Inventprise

Vaccines

GBS-06 Clin0 Strep; Shigella-04 RD Shigella; Klebsiella vaccine RD Klebsiella; RSV Vaccine RD RSV

Inventprise is developing innovative and affordable vaccines to bring health to the masses and provide protection against pathogenic strains of infectious diseases. Using their Linker Conjugation platform, Inventprise is creating vaccines that last-longer within patients enabling better coverage and a stronger immune response to be generated. The platform uses their proprietary scalable conjugation technology that can be used to create highly immunogenic and broad spectrum conjugate vaccines. Inventprise’s lead candidate, PCV-25, is a Pneumococcal Conjugate Vaccine, however their robust pipeline also includes investigational vaccines for group B streptococcus and Shigella.